# OnCo record nct06158841 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06158841/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06158841", "NCT06158841" ;
  schema:name "Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto"@en ;
  schema:alternateName "CERVINO"@en ;
  schema:description "A phase 3 trial of Carfilzomib, Pomalidomide, Elotuzumab in multiple myeloma, run by AbbVie, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06158841/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06158841> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-05-19" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:drugs <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/elotuzumab/>, <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/dexamethasone/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .